Chlamydia Infections – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Chlamydia Infections – Pipeline Review, H2 2019’, provides an overview of the Chlamydia Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chlamydia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections

– The report reviews pipeline therapeutics for Chlamydia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chlamydia Infections therapeutics and enlists all their major and minor projects

– The report assesses Chlamydia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chlamydia Infections”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Abera Bioscience AB

Abivax SA

BlueWillow Biologics Inc

Evofem Biosciences Inc

Genetic Immunity Inc

Lawrence Livermore National Laboratory

Lead Discovery Center GmbH

Merck & Co Inc

Microbiotix Inc

Prokarium Ltd

QureTech Bio AB

SATT IDF Innov SAS

Vault Pharma Inc

Vaxine Pty Ltd

Yaso Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chlamydia Infections Overview

Chlamydia Infections Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chlamydia Infections Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chlamydia Infections Companies Involved in Therapeutics Development

Abera Bioscience AB

Abivax SA

BlueWillow Biologics Inc

Evofem Biosciences Inc

Genetic Immunity Inc

Lawrence Livermore National Laboratory

Lead Discovery Center GmbH

Merck & Co Inc

Microbiotix Inc

Prokarium Ltd

QureTech Bio AB

SATT IDF Innov SAS

Vault Pharma Inc

Vaxine Pty Ltd

Chlamydia Infections Drug Profiles

Ab-03 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-196 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphora Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ChlamyDerm Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia trachomatis vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chlamydia vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEG-2S Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit CPAF for Chlamydia Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chlamydia Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Virulence for Chlamydia Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia Infections Dormant Projects

Chlamydia Infections Product Development Milestones

Featured News & Press Releases

Apr 20, 2017: New weapon in fight against antibiotic resistance discovered

Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice

Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology

Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia

Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection

Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Table 1: Number of Products under Development for Chlamydia Infections, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Universities/Institutes, H2 2019

Table 4: Products under Development by Companies, H2 2019

Table 5: Products under Development by Universities/Institutes, H2 2019

Table 6: Number of Products by Stage and Target, H2 2019

Table 7: Number of Products by Stage and Mechanism of Action, H2 2019

Table 8: Number of Products by Stage and Route of Administration, H2 2019

Table 9: Number of Products by Stage and Molecule Type, H2 2019

Table 10: Chlamydia Infections – Pipeline by Abera Bioscience AB, H2 2019

Table 11: Chlamydia Infections – Pipeline by Abivax SA, H2 2019

Table 12: Chlamydia Infections – Pipeline by BlueWillow Biologics Inc, H2 2019

Table 13: Chlamydia Infections – Pipeline by Evofem Biosciences Inc, H2 2019

Table 14: Chlamydia Infections – Pipeline by Genetic Immunity Inc, H2 2019

Table 15: Chlamydia Infections – Pipeline by Lawrence Livermore National Laboratory, H2 2019

Table 16: Chlamydia Infections – Pipeline by Lead Discovery Center GmbH, H2 2019

Table 17: Chlamydia Infections – Pipeline by Merck & Co Inc, H2 2019

Table 18: Chlamydia Infections – Pipeline by Microbiotix Inc, H2 2019

Table 19: Chlamydia Infections – Pipeline by Prokarium Ltd, H2 2019

Table 20: Chlamydia Infections – Pipeline by QureTech Bio AB, H2 2019

Table 21: Chlamydia Infections – Pipeline by SATT IDF Innov SAS, H2 2019

Table 22: Chlamydia Infections – Pipeline by Vault Pharma Inc, H2 2019

Table 23: Chlamydia Infections – Pipeline by Vaxine Pty Ltd, H2 2019

Table 24: Chlamydia Infections – Pipeline by Yaso Therapeutics Inc, H2 2019

Table 25: Chlamydia Infections – Dormant Projects, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Chlamydia Infections, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Targets, H2 2019

Figure 5: Number of Products by Stage and Targets, H2 2019

Figure 6: Number of Products by Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Routes of Administration, H2 2019

Figure 10: Number of Products by Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports